Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 83, Issue 4, 2003, Pages 248-252

  Shimada, Hideaki ^a   Nabeya, Yoshihiro ^a   Okazumi, Shin Ichi ^a   Matsubara, Hisahiro ^a   Shiratori, Tooru ^a   Aoki, Taito ^a   Sugaya, Makoto ^a   Miyazawa, Yukimasa ^a   Hayashi, Hideki ^a   Miyazaki, Shin Ichi ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CRP; Esophageal cancer; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NONBIOLOGICAL MODEL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041708071     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10275     Document Type: Article

References (29)

1. Daly JM, Kamell LH, Menck HR: National cancer database report on esophageal carcinoma. Cancer 1996;78:1820-1828.
2. Tachimori Y, Kato H: Diagnosis and surgery of esophageal cancer. Crit Rev Oncol Hematol 1998;28:57-71.
3. Isono K, Ochiai T, Okuyama K, et al.: The treatment of lymph node metastasis from esophageal cancer by extensive lymphadenectomy. Jpn J Surg 1990;20:151-157.
4. Isono K, Sato H, Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991;48:411-420.
5. Shimada H, Takeda A, Nabeya Y, et al.: Clinical significance of serum vascular endothelial growth factor in esophageal cancer patients. Cancer 2000;92:663-669.
6. Nabeya Y, Shimada H, Okazumi S, et al.: Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a useful prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 2000;94:940-949.
7. Shimada H, Takeda A, Nabeya Y, et al.: Prognostic significance of serum thymidine phosphrylase in the patients with esophageal squamous cell carcinoma. Cancer 2002;94:1947-1954.
8. Shimada H, Okazumi S, Matsubara H, et al.: Prognostic signifcance of serum p53 antibodies in the patients with esophageal squamous cell carcinoma. Surgery 2002;132:41-47.
9. Nakanishi H, Araki N, Kudawara I, et al.: Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002;99:167-170.
10. Nozoe T, Saeki H, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-201.
11. Miyata Y, Koga S, Nishikido M, et al.: Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001;58:161-164.
12. Deichmann M, Benner A, Waldmann V, et al.: Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000;19:301-307.
13. Kodama J, Miyagi Y, Seki N, et al.: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-110.
14. Falconer JS, Fearon KC, Ross JA, et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-2082.
15. Nielsen HJ, Christensen IJ, Sorensen S, et al.: Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7:617-623.
16. Sobin LH, Wittekind C: International union against cancer: TNM classification of malignant tumors. 5th edition. New York: Wiley-Liss; 1997.
17. Ritchite DG, Fuller GM: Hepatocyte-stimulating factor: A monocyte-derived acute-phase regulatory protein. Ann NY Acad Sci 1983;408:490-502.
18. Castell JV, Gomez-Lechon MJ, et al.: Interleukin6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-239.
19. Ljungberg B, Grankvist K, Rasmuson T: Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-1798.
20. Yoshida N, Ikemoto S, Narita K, et al.: Interleukin-6, tumor necrosis factor alpha, and interleukin-1 beta in patients with renal cell carcinoma. Br J Cancer 2002;86:1396-1400.
21. Ueno H, Okada S, Okusaka T, et al.: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296-301.
22. Heys SD, Ogston KN, Simpson WG, et al.: Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: Response and survival. Int J Oncol 1998;13:589-594.
23. Jee SH, Shen SC, Chiu HC, et al.: Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001;20:198-208.
24. Maccio A, Lai P, Santona MC, et al.: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998;69:248-252.
25. McMillan DC, Wotherspoon HA, Fearon KC, et al.: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995; 170:319-322.
26. Li M, Lotan R, Levin B, et al.: Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:545-549.
27. Husain SS, Szabo IL, Tamawski AS: NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002;97:542-553.
28. Farrow DC, Vaughan TL, Hansten PD, et al.: Use of aspirin and other non-steroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:97-102.
29. Funkhouser EM, Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-1119.